Physician profile
Robert E Thomas
NPI 1215727177
$1,141.89
in general payments reported to CMS, 2019-2025
20 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,141.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $142.10 | 2025 | Rybrevant, Carvykti, Erleada |
| Takeda Pharmaceuticals U.S.A., INC. | $119.79 | 2025 | Iclusig, Fruzaqla |
| Sanofi US Services INC. | $103.88 | 2025 | |
| Novartis Pharmaceuticals Corporation | $102.69 | 2025 | |
| Merck Sharp & Dohme LLC | $99.17 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
| Astrazeneca Pharmaceuticals Lp | $73.23 | 2025 | Imfinzi, Tagrisso, Enhertu |
| Celgene Corporation | $56.51 | 2025 | Reblozyl |
| Daiichi Sankyo INC. | $48.52 | 2025 | Enhertu, Datroway |
| Genzyme Corporation | $47.21 | 2025 | |
| Glaxosmithkline, LLC. | $45.43 | 2025 | Ojjaara, Zejula, Jemperli |
| Agios Pharmaceuticals, INC. | $40.92 | 2025 | Pyrukynd |
| Sobi, INC | $36.36 | 2025 | |
| Genmab U.S., INC. | $31.97 | 2025 | Epkinly |
| Geron Corporation | $31.02 | 2025 | Rytelo |
| Coherus Oncology, INC. | $30.31 | 2025 | Loqtorzi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $30.12 | 2025 | Polivy |
| Karyopharm Therapeutics INC. | $28.88 | 2025 | Xpovio |
| Acrotech Biopharma INC. | $25.03 | 2025 | Beleodaq |
| Incyte Corporation | $24.54 | 2025 | Zynyz |
| Legend Biotech USA INC. | $24.21 | 2025 | Carvykti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.